Retatrutide is one of the most promising weight loss drugs in development, and it is already being used by people outside of clinical trials. In this episode of the Rated Rx Podcast, pharmacists break down why educated patients are intentionally using an investigational drug that is not FDA approved, does not have a verified supply chain, and is labeled for research use only.

You will learn how retatrutide works as a triple agonist targeting GLP 1 GIP and glucagon, why early clinical trial data is generating excitement, and where the line gets crossed between understanding the science and bypassing safety systems. The discussion covers black market peptide sourcing, cold chain failures, contamination risk, dosing uncertainty, and why even expert level knowledge does not replace regulation.

The hosts also explain why compounding pharmacies refuse to make investigational drugs, how online research chemical markets operate, and what can go wrong when sterility purity and oversight are missing. This is a clear and honest conversation about impatience driven by science, weight loss desperation, and why waiting for FDA approval protects patients even when the data looks promising.

This podcast is intended for entertainment and informational purposes only.

Rated Rx Website

YouTube

Facebook

Instagram

TikTok